Skip to content

Participate in our active studies Subscribe to our Mailing List

AB Science

Masitinib and AB8939 – Two compounds with breakthrough mechanism of action

Home
Company
Science
Pipeline
News and Media
Investors
Masivet®
- About Masivet®
- Medical information and Pharmacovigilance
Careers
Contact

Search:

Home
Company
Science
Pipeline
News and Media
Investors
Masivet®
- About Masivet®
- Medical information and Pharmacovigilance
Careers
Contact

First half of 2020 results

You are here:

Home
News
2020
First half of 2020 results

30/09/2020 – AB Science reports its revenues for the first half of 2020

Post navigation

PreviousPrevious post:AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World’s Largest Multiple Sclerosis Research Conference NextNext post:Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society symposium

Related Posts

23/12/2020 Boursorama Interview of Alain Moussy

Boursorama interview of Alain Moussy, CEO of AB Science
December 23, 2020

Capital raise for a total amount of 15 million euros
December 21, 2020

Results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease
December 18, 2020

Masitinib in Alzheimer’s Disease Webcast Presentation
December 17, 2020

Results of the Extraordinary General Shareholders’ Meeting of December 16, 2020
December 17, 2020

Corrective press release regarding adverse events information from study AB09004
December 17, 2020

Search

Search:

Recent Posts

Revenues for the first half of 2024 and update on AB Science’s activities
AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million euros
AB Science announces a slight delay in the publication of its 2024 half-year financial report
AB Science announces the success of a 5.0 million euros capital increase
AB Science provides an update on the microtubule program AB8939
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024

AB SCIENCE
HEADQUARTER

3, Avenue George V – 75008 PARIS – FRANCE
Tel. : +33 (0)1 47 20 00 14
Fax. : +33 (0)1 47 20 24 11

GENERAL INQUIRIES

contact@ab-science.com

PRODUCT INQUIRIES

masivet@ab-science.com

JOB INQUIRIES

careers@ab-science.com

CLINICAL INQUIRIES

clinical@ab-science.com

MEDIA / FINANCIAL INQUIRIES

investors@ab-science.com

PHARMACOVIGILANCE

pharmacovigilance@ab-science.com
Fax : +33 1 47 20 10 82

© AB Science – All right reserved